To evaluate of adjuvant therapy using oxaliplatin and gemcitabine (GEMOX regimen) versus capecitabine alone chemotherapy in patients who underwent curative surgery for intrahepatic cholangiocarcinoma (ICC) -- a randomized control study.

chemotherapy: GEMOX vs capecitabine alone; adjuvant settings; primary endpoint: recurrence-free survival (RFS); second endpoint: overall survival after surgery (OS).

Inclusion Criteria:

• ECOG PS≤1;
• pathologically confirmed adenocarcinoma of bile duct;
• R1 resection or R0 resection with these risk factors: lymph node metastasis, lymphatic vessel or blood vessel invasion, multiple tumors, tumor size >5 cm, preoperative CA199>200 U/mL.
• postoperative liver function Child Pugh Class A, leukocyte count>1.5*10^9/L, platelet count>100*10^9/L, serum alanine aminotransferase <1.5*ULN
• no tumor recurrence or metastasis on baseline examination
• no history of radiotherapy or intervention therapy

Exclusion Criteria:

• hepatocellular carcinoma, mixed carcinoma of ICC and HCC, or hilar cholangiocarcinoma
• distant metastasis
• prothrombin time >14s
• severe cardiopulmonary dysfunction
• severe renal dysfunction
• bone marrow suppression before the initiation of therapy
• allergic to fluorouracil, gemcitabine, or platinum
• gemcitabine was used in combination with radiotherapy